Emergent BioSolutions Inc EBS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EBS is a good fit for your portfolio.
News
-
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
-
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
-
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
-
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
-
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
-
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
-
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
-
SHAREHOLDER ALERT: Morris Kandinov Investigating EBS, JRVR, EGIO, and HAFC; Shareholders are Encouraged to Contact the Firm
Trading Information
- Previous Close Price
- $2.07
- Day Range
- $1.96–2.15
- 52-Week Range
- $1.81–16.66
- Bid/Ask
- $2.00 / $2.05
- Market Cap
- $104.13 Mil
- Volume/Avg
- 1.8 Mil / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.09
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 2,500
Valuation
|
Metric
|
EBS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.09 |
Price/Cash Flow | — |
Price/Earnings
EBS
Financial Strength
|
Metric
|
EBS
|
|---|---|
Quick Ratio | 0.55 |
Current Ratio | 1.12 |
Interest Coverage | −7.06 |
Quick Ratio
EBS
Profitability
|
Metric
|
EBS
|
|---|---|
Return on Assets (Normalized) | −10.42% |
Return on Equity (Normalized) | −22.34% |
Return on Invested Capital (Normalized) | −9.80% |
Return on Assets
EBS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Wdkq | $81.2 Bil | |
MKKGY
| Merck KGaA ADR | Jlqxp | $76.0 Bil | |
HLN
| Haleon PLC ADR | Lqpz | $38.9 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ktfz | $11.3 Bil | |
VTRS
| Viatris Inc | Xnbb | $11.0 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Vjcnf | $10.8 Bil | |
CTLT
| Catalent Inc | Nslvry | $7.1 Bil | |
PRGO
| Perrigo Co PLC | Cjrgl | $4.1 Bil | |
ALKS
| Alkermes PLC | Lfjvm | $3.9 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Knptwm | $2.8 Bil |